financetom
Business
financetom
/
Business
/
Dixon Tech eyes ₹48,000 crore revenue boost over 6 years, banking on PLI 2.0 benefits
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dixon Tech eyes ₹48,000 crore revenue boost over 6 years, banking on PLI 2.0 benefits
Oct 27, 2023 6:19 AM

Electronic goods manufacturer Dixon Technologies is targetting revenues of ₹48,000 crore over the next six years as it hopes to benefit from the next round of government's production-linked incentives (PLI).

Share Market Live

NSE

Atul Lall, MD, Dixon Technologies told CNBC-TV18 that the company has filed the application for the IT PLI 2.0 under the hybrid domestic category. It has also committed to a capex of ₹250 crore over the six-year period.

On Thursday (October 27), Dixon Tech reported a 47.1% year-on-year (YoY) jump in second-quarter net profit to ₹113.4 crore. Total revenue was nearly 28% higher at ₹4,943.2 crore.

Lall also talked about one of the biggest drivers of growth for the company -- mobile phones. "Undoubtedly, mobile is going to be the largest trigger for Dixon’s growth and the numbers are going to be very healthy in the current as well as next fiscal,” he said.

Dixon has begun trial runs for Xiaomi and commercial production is expected to start next month. The target is to reach almost half a million units a month within a couple of quarters. For Nokia, the current run rate is around 1.5-2.0 million units with the company also eyeing the export market. Other customers in the mobile category will start adding to the revenue in the second half of the year, Lall said.

He expects the margin in the laptop business to be around 3%.

Watch the accompanying video for more

(Edited by : Shweta Mungre)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Annovis Bio Files Patents for Combination Therapies Using Buntanetap
Annovis Bio Files Patents for Combination Therapies Using Buntanetap
Oct 2, 2024
02:21 PM EDT, 09/30/2024 (MT Newswires) -- Annovis Bio ( ANVS ) said Monday it filed three new patents for combination therapies involving its lead compound buntanetap with Trulicity or Viagra, or both. The therapies aim to treat neurodegenerative diseases, including Alzheimer's and Parkinson's, the company said, adding that early data shows potential cognitive improvement in preclinical studies using these...
ARM Holdings Unusual Options Activity
ARM Holdings Unusual Options Activity
Oct 2, 2024
Whales with a lot of money to spend have taken a noticeably bearish stance on ARM Holdings ( ARM ). Looking at options history for ARM Holdings ( ARM ) we detected 51 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 45% with...
Asset manager TPG close to buying Germany's Techem for $7.8 bln, Financial Times reports
Asset manager TPG close to buying Germany's Techem for $7.8 bln, Financial Times reports
Oct 2, 2024
Sept 30 (Reuters) - U.S.-based asset manager TPG is close to finalizing a 7 billion euro ($7.80 billion) deal to acquire German metering firm Techem, the Financial Times reported on Monday, citing people familiar with the matter. TPG may reach an agreement to acquire Techem from Switzerland's Partners Group as soon as Monday, FT added. ($1 = 0.8977 euros) ...
US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals
US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals
Oct 2, 2024
02:26 PM EDT, 09/30/2024 (MT Newswires) -- Bristol-Myers Squibb Company ( BMY ) won a dismissal of a $6.4 billion lawsuit alleging it delayed a Federal Drug Administration approval process for a Celgene drug in order to avoid paying Celgene shareholders for meeting certain milestones. As part of its deal to acquire Celgene, Bristol-Myers Squibb ( BMY ) issued Celgene...
Copyright 2023-2026 - www.financetom.com All Rights Reserved